Evoke Pharma (EVOK) Stock Price, News & Analysis

Company Overview

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $4.85 to $5.30
• 50-Day Range: $4.17 to $5.49
• 52-Week Range: $3.54 to $12.32
• Volume: 5,738 shs
• Average Volume: 8,175 shs
• Market Capitalization: $7.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Evoke Pharma Stock Analysis - MarketRank™

Evoke Pharma scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evoke Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evoke Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evoke Pharma is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.94% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evoke Pharma does not currently pay a dividend.

Dividend Growth

Evoke Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.94% of the float of Evoke Pharma has been sold short.

Short Interest Ratio / Days to Cover

Evoke Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evoke Pharma has recently increased by 7.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Evoke Pharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Evoke Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180.00 in company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Evoke Pharma is held by insiders.

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed this year?

Evoke Pharma's stock was trading at $4.42 at the beginning of 2025. Since then, EVOK shares have increased by 9.0% and is now trading at $4.82.
View the best growth stocks for 2025 here.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.94) EPS for the quarter. The specialty pharmaceutical company had revenue of $2.65 million for the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 308.49% and a negative net margin of 71.32%.

When did Evoke Pharma's stock split?

Evoke Pharma shares reverse split on the morning of Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Evoke Pharma's major shareholders?

Top institutional investors of Evoke Pharma include Nantahala Capital Management LLC (9.95%) and Concourse Financial Group Securities Inc..
View institutional ownership trends.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVOK
• CUSIP: N/A
• CIK: 1403708
• Web: www.evokepharma.com
• Phone: (858) 345-1494
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.9936)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,790,000.00
• Net Margins: -71.32%
• Pretax Margin: -71.32%
• Return on Equity: -308.49%
• Return on Assets: -53.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $5.18 million
• Price / Sales: 1.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($9.26) per share
• Price / Book: -0.52

Miscellaneous

• Outstanding Shares: 1,490,000
• Free Float: 1,395,000
• Market Cap: $7.18 million
• Optionable: Not Optionable
• Beta: 0.16